Aplastic anemia
Conditions
Interventions
SA group:none
LSA group:levamisole hydrochloride
Sponsors
The First affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. All the patients meet a NSAA diagnostic criteria, and agree the immunosuppressive therapy. Diagnoses reference to The diagnostic and therapeutic criteria for hematologic diseases(Zhang Zhinan 2007), and The diagnosis and treatment of aplastic anemia (2016 UK guidelines); 2. 18-70years old, male or female; 3. liver and kidney function: the blood bilirubin is less than or equal to 2mg/dL (35 mol/L), AST/ALT in the upper limit of the normal value below 2 times, blood inosine is less than or equal to 177 umol/L; 4. heart function is normal: EF>50%; 5. no serious lung infection; 6. All cases had no history of cancer and chemotherapy history, immunology therapy.The control group without hematologic diseases, lupus or other immune disfunctions, allergic disease, Fanconi anemia; 7. consent signed by patients or their families.
Exclusion criteria
Exclusion criteria: 1. congenital hematopoietic failure, Fanconi anemia, or combined with bone marrow hyperplasia, leukemia, multiple myeloma, giant cell anemia, paroxysmal nocturnal hemoglobin or other blood diseases; 2. the HBV DNA copy number is greater than 1000/ml or the serum hepatitis B virus is not clear; 3. serum bilirubin > 2mg/dL (35 umol/L); ALT or AST > 2 times the normal value of the upper limit; alkaline phosphatase > 3 times the upper limit of the normal value; serum creatinine > 177 mol/L; 4. HIV positive; 5. other serious diseases that may limit the patient to participate in the study (e.g., the progressive infection, incontrollable diabetes, severe cardiac insufficiency or angina pectoris, etc.); 6. conditions are not suitable for immunosuppressive therapy; 7. pregnant or lactating women; 8. can not understand or follow the research program; 9. Patients under 16 years of age; 10. patients with a history of cancer, chemotherapy, or radiation therapy, immune system diseases or allergic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Routine blood test;Blood biochemistry;Cyclosporine concentration;Bone Marrow Examin; | — |
Secondary
| Measure | Time frame |
|---|---|
| electrocardiogram;echocardiography; | — |
Countries
China
Contacts
Public ContactShengyun Lin
The First affiliated Hospital of Zhejiang Chinese Medical University
Outcome results
None listed